Oncology News | pharmaphorum

News

Dr Yu Xia, founder, chairwoman, president and chief executive of Akeso

Akeso PD-1 inhibitor cleared as Keytruda challenger advances

Akeso has bagged an FDA approval for its PD-1 inhibitor penpulimab and reported new data on highly-touted PD-1/VEGF bispecific ivonescimab.

News

Hands uniting in the centre of a circle of children

Irish study promises to revolutionise childhood cancer care

A five-year genomics study that aims to transform the care of children with cancer and improve treatment success has launched in Ireland.

News

AstraZeneca joins Tempus, Pathos in cancer AI project

AstraZeneca has started work with Tempus and Pathos AI on a $200m project to build a comprehensive multimodal foundation model for oncology.

News

Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal

Cancer drug developer Veraxa Biotech has reached a deal to merge with a SPAC in a deal that will give it a Nasdaq listing and a $1.6bn-plus valuation.

News

Data readout puts J&J's bladder cancer drug back on track

New data in non-muscle-invasive bladder cancer (NMIBC) has backed up Johnson & Johnson's faith in its TAR-200 drug candidate.

News

Woman with breast cancer covering her chest with her hands

Enhertu poised to move first line in HER2+ breast cancer

New data could make HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first time.

Akeso PD-1 inhibitor cleared as Keytruda challenger advances

Irish study promises to revolutionise childhood cancer care

AstraZeneca joins Tempus, Pathos in cancer AI project

Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal

Data readout puts J&J's bladder cancer drug back on track

Enhertu poised to move first line in HER2+ breast cancer

AbbVie's Immunogen buy delivers rare cancer drug approval

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks